Cathie Wood shifts ark invest trades toward beaten-down GeneDx and early-stage biotech

In a fresh sign of rotation, Cathie Wood repositioned ARK Invest this week as ark invest trades shifted from mature tech leaders toward high-beta genomics and emerging innovation names.

Major GeneDx buy anchors January 12 moves

On January 12, regulatory filings showed Wood executing several significant portfolio shifts across multiple ARK exchange-traded funds. The firm moved capital away from established tech stocks and deeper into earlier-stage biotech companies.

The largest single transaction was a purchase of 133,191 shares of GeneDx Holdings, totaling $15.88 million, through the ARK Innovation ETF and the ARK Genomic Revolution ETF. GeneDx is described as a global leader in rare disease diagnosis and holds the largest genomic dataset in that niche.

Importantly, the buy came immediately after GeneDx shares fell 11.9% on January 12. The drop followed company guidance that disappointed investors, even though preliminary fiscal year 2025 results were considered strong. However, ARK used the weakness to scale into the position.

Biotech additions highlight risk-on stance

Alongside GeneDx, ARK increased exposure to several other high-growth biotech names. Wood bought 99,292 shares of Intellia Therapeutics for about $1.13 million. That purchase followed a 10.2% surge in Intellia’s stock price on the same day, underscoring ARK’s conviction despite near-term volatility.

Moreover, the firm added 49,963 shares of 10X Genomics after that stock declined 3.2%. Wood also purchased 17,748 shares of Personalis, extending a recent pattern of incremental buying in the company. These moves collectively reinforce ARK’s preference for earlier-stage genomics and gene therapy platforms.

That said, the shift was not limited to small-cap biotech. The pattern across the day suggests a broader tilting of risk exposure within the portfolio, away from long-established players and toward platforms that ARK believes could benefit from multi-year innovation cycles.

Illumina sale marks rotation from established genomics

On the selling side, Wood exited a substantial slice of Illumina. ARK offloaded 91,312 shares for proceeds of about $13.29 million. The sale implies a rotation away from established genomics leaders and into earlier-stage companies in the same ecosystem.

Illumina has rallied nearly 48% over the past six months, giving ARK an opportunity to lock in gains. However, the timing also aligns with Wood’s ongoing strategy of reallocating capital from mature winners into businesses she sees as earlier in their growth curves.

This move, combined with the GeneDx and Intellia purchases, underscores how ark invest trades are increasingly focused on perceived upside from disruptive platforms rather than incumbents with more predictable growth trajectories.

Meta and large-cap tech trims

Beyond genomics, ARK executed notable sales in big-cap technology. Last week, the firm sold roughly $12.7 million in Meta Platforms shares across the ARK Innovation ETF, ARKW, and ARKF funds. The reduction reflects a broader pivot away from large-cap social media and more mature tech franchises.

On January 12, ARK also trimmed several other positions. The firm sold about $2.61 million in Natera shares and $5.15 million in Teradyne stock. Wood further reduced exposure to Beam Therapeutics by approximately $1.11 million, while also executing a smaller sale in Ionis Pharmaceuticals.

Collectively, these cuts indicate that ARK is selectively harvesting gains and reducing risk in companies that have already benefited from the current market cycle. However, the freed-up capital is not remaining in cash; instead, it is being redirected to earlier-stage innovation themes.

Exposure grows in advanced air mobility

While trimming mature tech and some established biotech names, ARK added to advanced air mobility holdings. The ARK Space Exploration & Innovation ETF increased positions in Joby Aviation and Archer Aviation, both developers of electric vertical takeoff and landing, or eVTOL, aircraft.

These companies are still in pre-commercial phases, but they sit at the intersection of aerospace, electrification, and automation. Moreover, Wood has repeatedly highlighted air mobility as a long-term disruptive theme, and the latest buys further align ARK’s portfolio with that thesis.

Other innovation-linked moves included a fresh purchase of Deere & Company stock. ARK’s interest there centers on automation and precision technologies in construction and agriculture, sectors that could see productivity gains from robotics and data-driven machinery.

Portfolio reshaping across multiple ETFs

Additional selling activity last week extended beyond Illumina and Meta. ARK trimmed holdings in Roku and Palantir Technologies, both of which have already experienced strong rallies in the recent period. That said, ARK did not fully exit these names, instead opting for measured reductions.

The cumulative trading pattern shows Wood channeling capital away from companies considered more mature in the current market cycle and toward emerging innovation sectors. These include cutting-edge biotech, autonomous and electric transport, and advanced manufacturing platforms tied to automation.

Moreover, the breadth of activity across the ARK Innovation ETF, ARK Genomic Revolution ETF, ARKW, ARKF, and the ARK Space Exploration & Innovation ETF highlights an integrated, cross-fund rebalancing rather than isolated stock-specific decisions.

Strategic emphasis on early-stage genomics and innovation

Wood’s latest biotech purchases reveal a clear tilt toward genomics and gene therapy companies that remain at earlier development stages. Names like GeneDx Holdings, Intellia Therapeutics, and Personalis exemplify her willingness to accept volatility in exchange for potential asymmetric upside.

By contrast, the sales of Illumina and Meta Platforms represent partial exits from more established market leaders with large existing footprints. However, rather than signaling a retreat from innovation, the changes show ARK concentrating capital in segments it views as underpriced relative to their long-term disruption potential.

In total, ARK’s recent trades span more than $50 million in combined buy and sell transactions across multiple sectors and ETFs. The activity illustrates a dynamic approach to portfolio management as Wood leans into early-stage biotech, advanced air mobility, and automation-driven manufacturing while paring back exposure to some of the market’s best-known growth names.

Overall, ARK’s January moves underline an aggressive rotation from mature tech and incumbent genomics toward higher-risk, higher-reward innovators, positioning the firm’s funds to capture potential upside from the next wave of disruptive technologies.